Moran Wealth Management LLC Takes Position in ADMA Biologics Inc (NASDAQ:ADMA)

Moran Wealth Management LLC acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 40,056 shares of the biotechnology company's stock, valued at approximately $795,000.

A number of other large investors have also added to or reduced their stakes in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in ADMA Biologics by 1.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after purchasing an additional 645 shares during the period. Oregon Public Employees Retirement Fund boosted its position in ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock worth $954,000 after purchasing an additional 700 shares during the period. Summit Investment Advisors Inc. boosted its position in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after purchasing an additional 746 shares during the period. Mutual of America Capital Management LLC boosted its position in ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after purchasing an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System boosted its position in ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after purchasing an additional 897 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.24 during trading hours on Friday, reaching $18.16. The stock had a trading volume of 4,944,670 shares, compared to its average volume of 3,716,139. The stock's fifty day simple moving average is $20.63 and its 200 day simple moving average is $18.76. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 12 month low of $10.21 and a 12 month high of $25.67. The firm has a market capitalization of $4.34 billion, a PE ratio of 21.36 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same quarter last year, the business posted $0.08 earnings per share. ADMA Biologics's revenue was up 40.2% compared to the same quarter last year. On average, equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of research reports. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Finally, Raymond James Financial increased their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th.

Insider Activity

In other news, Director Steve Elms sold 92,941 shares of the firm's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $21.69, for a total transaction of $2,015,890.29. Following the sale, the director now owns 2,031,730 shares in the company, valued at approximately $44,068,223.70. This trade represents a 4.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director now owns 94,830 shares in the company, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.